・ImmunoACT was founded by Dr Rahul Purwar and incorporated in 2018. It is a spinoff of his bio-science Immunoengineering lab from IIT Bombay which is the premier Science and Technology Institute in India, founded in the year 1958.
・ChimericAntigen Receptor (CAR) T cell therapy has shown enormous potential to revolutionize cancer treatment, and is an FDA approved therapy in USA.
・Currently the therapy is available at an exorbitant price close to USD 1 mio and hence not accessible to millions of terminally-ill patients in the low and middle income countries like India.
・ImmunoACT has indigenously invented the Novel Humanized CAR T therapy which is in advanced stages of human clinical trials for certain types of cancers, more specifically Acute Lymphoblastic Leukemia (ALL) and Diffused Large B Cell Lymphoma (DLBCL).
・This CART Technology has huge potential in curing various types of cancers, including solid tumours that are otherwise non-treatable through current medicine.
・ImmunoACT is also working to use this technology to cure other auto-immune diseases like Sickle Cell Anaemia which has very high prevalence in India.
・Lastly, beyond the commercial success, the social impact of our technology will be significant in India and other developing countries in providing affordable healthcare.
ImmunoACT has pioneered CART Technology and is an indigenously created innovation, first of its kind in India. The commitment and perseverance shown by Dr Rahul Purwar over the last 7 years to bring this research project to reality and complete the Translational work and finally commercialize it is a phenomenal achievement and an inspiration to budding entrepreneurs in the field of science and technology. The team also leveraged the various resources and partnerships optimally with Tata Memorial Centre for Cancer research, IIT Bombay and other institutions to create an ecosystem for its successful completion.
His work is now patented and also peer-reviewed in the prestigious AACR journal.
Lastly, this is a great Indian success story of leveraging deep technology for a significant social impact. In coming years, thousands of patients who otherwise would be terminally ill will be able to afford this therapy and lead healthy lives.